Abstract Perfluorooctanoic acid is a ligand for peroxisome proliferator-activated receptor (PPARa). Ammonium perfluorooctanoate (APFO) at 0.1 and 0.3 mg/kg doses activated mouse PPARa, but not human PPARa. This study aimed to clarify whether milligram-order APFO can activate human PPARa, and the receptor is involved in APFOinduced chronic hepatic damage. Male Sv/129 wild-type (mPPARa), Ppara-null, and humanized PPARa (hPPARa) mice (8 weeks old) were divided into three groups. The first was treated with water and the other two with 1.0 and 5.0 mg/kg APFO for 6 weeks, orally, respectively. Both doses activated mouse and human PPARa to a similar or lower degree in the latter. APFO dose dependently increased hepatic triglyceride levels in Ppara-null and hPPARa mice, but conversely decreased those in mPPARa ones. APFO-induced hepatic damage differed markedly among the three genotyped groups: single-cell necrosis was observed in all genotyped mice; inflammatory cells and macrovesicular steatosis only in Ppara-null mice; and microvesicular steatosis and hydropic degenerations in hPPARa and Ppara-null mice. The molecular mechanism underlying these differences may be attributable to those of gene expressions involved in lipid homeostasis (PPARa, b-and x-oxidation enzymes, and diacylglycerol acyltransferases) and uncoupling protein 2. Thus, milligramorder APFO activated both mouse and human PPARa in a different manner, which may reflect histopathologically different types of hepatic damage.
Introduction
Perfluorooctanoic acid (PFOA) (CAS, , an organofluoro compound, is used in industrial surfactants, emulsifiers, and numerous consumer products (Butenhoff et al. 2006) . Because the biological half-life in humans is reported as 3.5-4.4 years (Olsen et al. 2007 ), PFOA will probably be added to the list of Persistent Organic Pollutants in the near future (World Wildlife Fund 2005) .
A variety of toxicities associated with PFOA exposure have been investigated and revealed by many studies using ammonium perfluorooctanoate (APFO). Since PFOA is hardly excreted from the body (Kennedy et al. 2004 ) and is accumulated mostly in the liver (Lau et al. 2007 ), many studies have focused on the risk of hepatic damage, such as peroxisome proliferation (Nakamura et al. 2009 ), hepatocyte necrosis (Butenhoff et al. 2002) , hepatocellular adenoma (Biegel et al. 2001) , and hepatobiliary injury (Minata et al. 2010) . Recently, though Minata et al. (2010) showed that APFO caused cholestasis, this finding was seen mainly in peroxisome proliferator-activated receptor a (Ppara)-null mice, not mPPARa mice. Wolf et al. (2008a) reported that lipid droplets were characteristically observed in the livers of Ppara-null mice, but not in mPPARa mice. Thus, these results suggest that PPARa may play an important role in the pathogenesis of APFO-induced hepatosteatosis and cholestasis. However, its precise mechanism has not yet been fully understood.
Epidemiologically, PFOA may influence lipid metabolism: Olsen et al. (2003a) reported a positive association between PFOA and serum total cholesterol (TC) and triglycerides (TG). In contrast, no such association was reported in another factory (Olsen et al. 2003b) . Therefore, it is very important to clarify whether PFOA influences the lipid metabolism using experimental animals.
Since PFOA is an agonist for PPARa (Ikeda et al. 1985) , its activation enhances the activities of peroxisomal and mitochondrial b-oxidation enzymes for fatty acids and inhibits the secretion of very low-density lipoproteins and cholesterol from the liver, as well as reducing total cholesterol and TG in serum and the accumulation of lipids in the liver (Berthiaume and Wallace 2002) . However, the functional activation is thought to differ among species. Additionally, constitutive expression of PPARa is quite different between mice or rats and humans, whose expression is thought to be 1/10 of the experimental animals (Palmer et al. 1998) . PPARa-humanized (PPARa Tet-OFF ) mice that expressed human PPARa only in the liver of Ppara-null background mice have been established (Cheung et al. 2004 ). This mouse model has been recognized as a useful tool in determining the human PPARa function. As for the effects of Wy-14,643 on hepatic peroxisomal and mitochondrial b-oxidation enzymes, there were few differences in the inductions between mPPARa and hPPARa mice. Ramdhan et al. (2010) reported that one of the trichloroethylene metabolites, trichloroacetic acid, activated not only mouse PPARa but also human PPARa, though the exposure concentration of trichloroethylene was 1,000 and 2,000 ppm, respectively. However, the fact that expressions of human PPARa mRNA and protein are higher in hPPARa mice than in those of mPPARa (Nakamura et al. 2009 ) may suggest a weaker function of human PPARa compared with mouse PPARa. Indeed, although microgram-order APFO was unable to activate human PPARa, it did activate mouse PPARa (Nakamura et al. 2009 ). Therefore, it is very important to clarify whether APFO that is higher than that in a previous study (Nakamura et al. 2009 ) can activate human PPARa and also to determine how the species difference in the function is involved in PFOA-induced hepatic damage when we extrapolate from animal to human data.
Additionally, PFOA is also found to be an agonist for PPARc (Vanden Heuvel et al. 2006) , which has antiinflammatory power (Jiang et al. 1998) , even though contrary opinions have been reported (Chawla et al. 2001 ). This receptor is also accepted as a master transcriptional regulator of lipid and glucose metabolism (Spiegelman 1998) .
In this study, we compared the effects of relatively high dosages of APFO (0, 1.0, and 5.0 mg/kg) on the PPARa and the target gene expressions as well as the involvement of this receptor in hepatic damage using wild-type, Pparanull, and hPPARa mice. The molecular mechanisms were also clarified by analyzing the mRNA and protein expressions of related genes. Although relatively low-dose APFO could not activate human PPARa (Nakamura et al. 2009 ), higher doses clearly activated the receptor. Our results also suggest that the species difference in the function may determine the characteristic features of hepatic damage caused by PFOA.
Materials and methods

Experimental animals
This study was conducted according to the Guidelines for Animal Experiments of the Nagoya University Animal Center. Three genotyped male and female mice, i.e., wildtype (mPPARa), Ppara-null (Lee et al. 1995) , and hPPARa Tet-OFF (hPPARa) (Cheung et al. 2004 ) mice with an Sv/129 genetic background were bred and reared as described elsewhere (Nakamura et al. 2009 ). All mice were housed in a temperature-and light-controlled environment (25°C, 12 h light/dark cycle) and maintained on stock rodent chow (Nippon Clea, Tokyo, Japan) and tap water ad libitum. At 8 weeks old, the offspring male mice (n = 8-10) of each strain were assigned to the following treatment groups: treated with distilled water daily for 6 weeks by gavage (control group); treated with 1.0 or 5.0 mg/kg APFO (Tokyo Kasei Kagaku, Tokyo, Japan), respectively, for 6 weeks by gavages (Table 1 ). Since 0.1 and 0.3 mg/kg APFO activated mouse PPARa, but not human PPARa (Nakamura et al. 2009 ), about tenfold doses were selected in this experiment. Since we planned to investigate not only PPARa-directed hepatic damage but also reproductive toxicity of PFOA, we selected six-week exposure to the chemicals. The results of reproductive toxicity will be reported elsewhere. Macroscopically, there was no abnormal sign in all animals throughout the treatments. On the day following the last dose (18-20 h later), all mice were killed by decapitation, and the blood and livers were removed. A part of each liver was fixed by 10% buffered formalin. The remaining liver samples were snap frozen in liquid nitrogen and stored at -80°C until used. Plasma was collected after centrifuging blood at 3,500g for 10 min and stored at -80°C until used. The numbers of samples except for the histopathological analyses used were indicated in the Tables and Figure legends , and all measurements were performed in duplicate or triplicate.
Analysis of protein concentrations
Each tissue was homogenized with a threefold volume of 10 mM phosphate buffer (pH 7.4) containing 0.25 M sucrose. Protein concentrations of the homogenate and nuclear fraction samples were measured using a Protein Assay Kit (Bio-Rad, Tokyo, Japan).
Western blotting
A nuclear fraction was extracted from a part of the frozen liver using a CelLytic TM NuCLEAR TM Extraction Kit (SIGMA, Tokyo, Japan). The nuclear fractions (NFjB p65, p50, p52, and PPARa) and liver homogenates (other proteins) for electrophoresis were subjected to 10 or 12.5% polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Immunostaining was conducted as described elsewhere (Nakajima et al. 2000) .
Real-time quantitative PCR
Total RNA was isolated from the liver using the RNeasy Mini Kit (QIAGEN, Tokyo, Japan). Real-time quantitative PCR analysis was performed as described elsewhere (Nakamura et al. 2009; Ramdhan et al. 2010 ).
Lipid concentrations in plasma and liver
Lipid from livers was extracted using the method of Folch et al. (1957) . TG and TC in the liver and plasma were measured using TG-IE and T-Cho E kits (Wako, Osaka, Japan), respectively.
Histopathological analysis
Small blocks of liver tissues from each mouse (five animals randomly selected from each group) fixed in 10% neutral buffered formalin were embedded in paraffin and sliced into 4-lm sections. Tissue sections of the livers were stained with hematoxylin and eosin (H & E) and examined under a BZ-8000 (Keyence, Osaka, Japan) light microscope. Severities of steatosis, lobular inflammation, and hepatocyte degeneration were scored by a pathologist in a blinded fashion referring to the methods of Brunt et al. (1999) and Ramdhan et al. (2010) with the following minor modifications: (1) grade of steatosis: 0, none (0-5% of parenchymal involvement by steatosis); 1, mild (5-33% of parenchymal involvement by steatosis); 2, moderate (33-66%); 3, severe ([66%); (2) grade of lobular inflammation: 0, none; 1, mild; 2, moderate; 3, severe; (3) singlecell necrosis and hepatocyte hydropic degeneration: 0, absent; 1, present; 2, frequent.
Alanine aminotransferase measurements
Plasma ALT activities were measured using a Transaminase C II Test kit purchased from Wako (Osaka, Japan).
Statistical analysis
The Steel-Dwass method in case of pathological scoring and Tukey-Kramer HSD post hoc test in the other cases were conducted to compare the effects of treatment among each treated group of each genotyped mouse, and also among the control groups of mPPARa, Ppara-null, and hPPARa mice. Values of P \ 0.05 were considered to indicate statistical significance.
Results
Body and liver weight
No significant differences were observed in body weight before and after APFO treatments among the control groups of mPPARa, Ppara-null, and hPPARa mice (Table 1) . APFO treatments did not induce an increase in body weight in any genotyped mice, whereas they did increase the liver weight and the ratio of liver per body in all genotyped mice in a dose-dependent manner. In the 1.0 mg/kg treatment group, the ratio increases were most prominent in mPPARa mice (1.9-fold)), while in the 5.0 mg/kg dose group, they were most prominent in Pparanull mice (2.9-fold).
Histopathological evaluation
Apparent macrovesicular and microvesicular steatosis were not observed in the liver of control Ppara-null mice Ppara-null 21.1 ± 2.5 (9) 21.1 ± 2.8 (9) 21.8 ± 1.5 (9) hPPARa 20.3 ± 1.9 (9) 19.4 ± 1.0 (9) 20.3 ± 2.5 (10)
Body weight (g) after APFO treatments mPPARa 24.8 ± 1.0 (8) 24.7 ± 2.2 (8) 23.5 ± 1.7 (9) Ppara-null 24.2 ± 2.4 (9) 23.6 ± 2.8 (9) 25.6 ± 2.5 (9) hPPARa 23.5 ± 1.3 (9) 22.3 ± 1.7 (9) 23.5 ± 2.1 (10) Ppara-null 4.56 ± 0.38 (9) 6.68 ± 1.27 (9)* 13.06 ± 1.16 (9)* ,# hPPARa 4.37 ± 0.30 (9) 6.67 ± 0.42 (9)* 10.56 ± 0.91 (10)* ,#
Plasma ALT (IU/L) mPPARa 6.7 ± 0.9 (8) 7.6 ± 2.6 (8) 15.6 ± 8.6 (9)* ,# Ppara-null 7.2 ± 1.6 (9) 8.6 ± 2.5 (9) 9.3 ± 1.8 (9)* hPPARa 6.5 ± 1.3 (9) 8.1 ± 2.7 (9) 8.9 ± 1.5 (10)* Plasma TG (mg/dl) mPPARa 156.4 ± 43.6 (8) 107.3 ± 27.4 (8)* 77.6 ± 19.0 (9)* Ppara-null 168.7 ± 80.6 (9) 183.2 ± 67.2 (9) 164.8 ± 57.7 (9) hPPARa 195.9 ± 69.2 (9) 209.5 ± 58.7 (9) 142.6 ± 36.9 (9) # Hepatic TG (mg/g) mPPARa 13.3 ± 1.5 (8) 23.4 ± 5.5 (8)* 11.8 ± 3.8 (9) # Ppara-null 19.6 ± 11.0 (9) 58.7 ± 38.6 (9)* 106.3 ± 34.9 (9)* ,# hPPARa 17.4 ± 4.4 (9) 34.4 ± 15.7 (9)* 51.7 ± 11.9 (10)* ,# Plasma TC (mg/dl) mPPARa 66.9 ± 22.3 (8) 63.8 ± 17.6 (8) 39.4 ± 11.9 (9)* ,# Ppara-null 109.5 ± 27.7 (9) 84.5 ± 16.3 (9) 57.8 ± 21.5 (9)* ,# hPPARa 106.6 ± 13.3 (9) 99.2 ± 27.2 (9) 83.5 ± 25.4 (10)
Hepatic TC (mg/g) mPPARa 3.7 ± 0.8 (8) 3.6 ± 0.8 (9) 5.3 ± 1.3 (9)
Ppara-null 4.5 ± 0.6 (9) 6.8 ± 2.5 (9) 10.4 ± 4.4 (9)* hPPARa 5.4 ± 0.8 (9) 6.7 ± 1.5 (9) 6.1 ± 1.0 (10) (Fig. 1b , Table 2 ). APFO induced macrovesicular steatosis only in the liver of Ppara-null mice in dose-dependent fashion, while it induced microvesicular steatosis in both Ppara-null as well as hPPARa mice; the degree of these fat accumulations was not influenced by APFO dosages (Fig. 1, Table 2 ). High-dose APFO (5.0 mg/kg) induced lobular inflammation only in Ppara-null mice. Although high-dose APFO induced single-cell necrosis in all genotyped mice, the severity appeared to be greater in mPPARa mice than in Ppara-null and hPPARa mouse lines. Interestingly, high-dose APFO characteristically induced hydropic degeneration of hepatocytes in Ppara-null (arrows in Fig. 1k ) and hPPARa mice (Fig. 1i ), but not in mPPARa mice. Hypertrophied hepatocytes with prominent eosinophilic cytoplasm, which sometimes appear in the livers of mice treated with potent PPARa activators, were detected in APFO-treated mPPARa (Fig. 1g , arrowheads in Fig. 1j ) and hPPARa mice (Fig. 1i) . We might note that hepatocholangiole proliferation was only fleetingly observed in Ppara-null mice exposed to 5.0 mg/kg PFOA, but obvious cholestasis, evidenced by intracellular bile droplets and a bile plug, was not observed in the livers of any genotyped mice.
Plasma ALT levels
High-dose APFO increased plasma ALT activities in all genotyped mouse lines, though the elevations were very small, and no differences were noted in these increases among three genotyped mice (mPPARa mice, 2.3-fold vs control; Ppara-null, 1.3-fold; hPPARa mice, 1.4-fold) (Table 1) .
Plasma and hepatic TG and TC levels APFO treatment dose dependently decreased plasma TG levels in mPPARa mice (0.70-fold at 1.0 mg/kg and 0.50-fold at 5.0 mg/kg), while not influencing the levels in Ppara-null and hPPARa mice. In contrast, APFO did not influence hepatic TG levels in mPPARa mice, though 1.0 mg APFO slightly increased those levels. APFO treatments significantly increased hepatic TG levels in Pparanull mice (3.2-fold and 5.3-fold at 1.0 and 5.0 mg/kg, respectively), but only slightly increased them in hPPARa mice at 1.0 and 5.0 mg/kg (2.0-fold and 3.0-fold, respectively). Consistent with histopathological findings, hepatic TG contents in the control Ppara-null mice were similar to those in the control mPpara mice and hPPARa mice. High-dose APFO (5.0 mg/kg) treatment dose dependently decreased plasma TC levels in mPPARa and Pparanull mice, but not in hPPARa mice. In contrast, PFOA increased hepatic TC levels in Ppara-null mice, but not in mPPARa and hPPARa mice.
Analysis of mRNA levels
Because APFO influenced plasma and hepatic TG levels differently in three genotyped mice, we investigated hepatic b-oxidation enzymes that are PPARa-target genes and are involved in fatty acid metabolism. PPARa mRNA expression was significantly greater in hPPARa mice than in mPPARa mice, results similar to those of Nakamura et al. (2009) (Fig. 2) . Constitutive expressions of CYP4A10, PT, and VLCAD mRNA were significantly lower in Ppara-null mice than in mPPARa and hPPARa mice, while those of PH were lower only in hPPARa mice.
Although APFO treatment did not influence the PPARamRNA levels in either mPPARa or hPPARa mice, increased expressions of hepatic PPARa-target genes, CYP4A10, PT, PH, MCAD, VLCAD, and proliferation cell nuclear antigen (PCNA) were observed in both mouse lines. In general, their increases were the same (VLCAD, MCAD, and PCNA) or roughly twofold greater (PT and PH) in the former than in the latter, while CYP4A10-mRNA was around fivefold higher in mPPARa mice compared with that in hPPARa mice. Next, we measured the effects of APFO treatment on triglyceride-synthesizing enzymes (Yen et al. 2008) . APFO was found to increase DGAT1-mRNA levels in Ppara-null and hPPARa mice (1.7-to 2.2-fold), but at a 5.0 mg/kg dose alone it decreased the mRNA in mPPARa (0.7-fold). In contrast, APFO slightly reduced DGAT2-mRNA levels in mPPARa and hPPARa mice (*0.6-fold). Because DGAT1 and 2 are PPARc target genes (Ranganathan et al. 2006; Festuccia et al. 2009 ), the expression was also investigated: both APFO dosages increased PPARc mRNA levels in Ppara-null mice in a dose-dependent fashion (7-to 13-fold), and only slightly in hPPARa mice (2-to 3-fold); in mPPARa mice, they increased only at a 1.0 mg/kg dose (3.5-fold).
Since obvious inflammatory cell infiltration was seen in Ppara-null mice, but not in mPPARa and hPPARa mice, we measured NFjB subunits: APFO treatments slightly induced p65-mRNA levels only in Ppara-null mice (2.2-fold), but even decreased them in mPPARa (0.6-fold); in p50-mRNA, PFOA significantly decreased at 1.0 and 5.0 mg/kg dosages in mPPARa mice (0.7-to 0.8-fold). As for p52-mRNA, the low-and high-dose APFO significantly raised the levels in Ppara-null (1.5-fold and 1.9-fold) and the high dose in mPPARa mice (1.4-fold), although none of them increased the mRNA levels in hPPARa mice. We also measured the pro-inflammatory cytokine TNFa-mRNA (Moriya et al. 2009 ) and a mitochondrial antioxidant UCP2-mRNA (Nègre-Salvayre et al. 1997) . High-dose PFOA significantly increased TNFamRNA in mPPARa, Ppara-null, and hPPARa mice (2.9-fold, 1.9-fold, and 1.9-fold, respectively). An obvious difference was observed in the increase in UCP2-mRNA levels; the increase was dose dependent, with the high dose increasing by 28-fold in mPPARa mice, while it raised the levels fivefold in hPPARa mice. No increase in mRNA was observed in Ppara-null mice. Western blot analysis
In the control group, PPARa expression was greater in hPPARa mice than in mPPARa mice and surprisingly decreased APFO treatments only in the latter (Fig. 3) . The expressions of PT and PH were significantly lower in Pparanull mice than in mPPARa and hPPARa mice, while that of VLCAD was significantly higher in hPPARa mice than in mPPARa and Ppara-null mice. The levels of PT, PH, and VLCAD in mPPARa mice appeared to reach the maximum at low-dose APFO and did not increase further at the high dose, while in hPPARa mice, the increase tended to elevate in a dose-dependent fashion. APFO elevated MCAD protein only in mPPARa mice at the high dose. The protein expression of the cell proliferation marker, PCNA, was higher in all APFO-treated mPPARa and hPPARa mice compared with respective controls. The levels of p65 and p52 protein in the control group were lower in Ppara-null and hPPARa mice than in mPPARa mice, while TNFa levels were higher in hPPARa mice than in mPPARa and Ppara-null mice. APFO treatments increased the protein of p65 only in Ppara-null (1.8-to 1.9-fold) and hPPARa mice (1.4-to 1.5-fold), but did not increase p50 levels. In contrast, APFO increased p52 levels in all genotyped mice at both dosages (1.5-to 2.0-fold). High-dose APFO significantly increased TNFa levels in all genotyped mice, while increases were also observed when compared with the low-dose treatment.
Discussion
We reported that microgram-order APFO could not activate human PPARa but did activate mouse PPARa (Nakamura et al. 2009 ). The current experiment has clearly shown that milligram-order APFO (1.0-5.0 mg/kg) activated both PPARa to a similar or even smaller extent in human PPARa. Therefore, the PPARa function of humans might be weak compared with that of mice, due to the higher expression of human PPARa compared with that of mouse PPARa in the mouse livers used in this experiment. In that connection, Takacs and Abbott (2007) measured the lowest effective concentrations of PFOA at which mouse and human PPARa were activated in an in vitro system, showing them to be 10 and 30 lM, respectively. Wolf et al. (2008b) also reported that the activation of mouse PPARa by APFO was generally higher compared with that of human PPARa. Thus, there were clear-cut species differences in PPARa activation between mice and humans, similar to those by trichloroethylene exposure (Ramdhan et al. 2010) .
The first point for discussion in the present study is that APFO-induced hepatic damage was quite different Fig. 3 Protein expressions of PPARa and the related genes in livers from mPPARa, Ppara-null and hPPARa mice treated with APFO. a Representative Western blot analyses. As an internal standard, GAPDH was stained. b Each band was quantified by densitometric analysis. Histogram presents means ± SD for 8-10 mice per group, and the mean from each control group in mPPARa mice was assigned a value of 1.0. *Significantly different from respective control (0 mg/kg) group (P \ 0.05).
#
Significantly different from respective low-dose (1.0 mg/kg) group (P \ 0.05). Significantly different from control of mPPARa (P \ 0.05). § Significantly different from control of Pparanull mice (P \ 0.05) histopathologically among mPPARa, Ppara-null, and hPPARa mice, unlike such differences in plasma ALT activities. Hypertrophic hepatocytes with eosinophilic cytoplasm were observed in mPPARa and hPPARa mice, suggesting the presence of PPARa activation. This finding was consistent with the results that typical PPARa target genes (e.g., CYP4A10, PH, PCNA, and UCP-2) were induced in both mouse groups. In contrast, inflammatory cell infiltrations were frequently observed in Ppara-null mice, which were also supported by the inflammation signaling analysis referring to p65 mRNA and protein expressions. It is of interest to note that APFO decreased p65 and p50 expressions in mPPARa mice, which may have resulted from the strong activation of PPARa in the mouse line. Mouse PPARa induced by APFO treatment may completely inhibit the import of p50 and p65 directly into the nucleus or via IjBa and thereby the inhibiting inflammation, since this receptor was shown to possess such a function (Moriya et al. 2009 ). However, the function of human PPARa may be weak compared with that of mice and thus could not fully inhibit the inflammatory signaling in hPPARa mice as it does in mPPARa mice. The increase in p52 mRNA and protein were not correlated with inflammatory cell infiltrations and may be related instead to the increase in plasma ALT activity in all genotyped mice.
Our second point involves the histopathological differences in steatosis among three genotyped mice after APFO treatments: microvesicular steatosis was seen in Ppara-null and hPPARa mice, whereas macrovesicular steatosis was observed only in Ppara-null mice. These findings were not replicated in mPPARa mice. In line with these results, APFO treatments also increased hepatic TG and TC levels in Ppara-null and hPPARa mice, though the increase in TC was not significant in the latter mouse line. In mPPARa mice, 5.0 mg/kg dose decreased the TG level, which may be related to the elevation of b-oxidation enzymes. APFO treatments induced fatty acid b-oxidation enzymes more in mPPARa mice than in hPPARa mice, but very few in Ppara-null mice. In addition, APFO increased the expressions of DGAT1 in Ppara-null and hPPARa mice more prominently compared with those in mPPARa mice. As for DGAT2, the exposure decreased the expressions in mPPARa and hPPARa mice, but did not influence those in Ppara-null mice. Taken together, less or lower induction of fatty acid b-oxidation enzymes and higher induction of DGAT1 by APFO may, in part, reflect the increase of macrovesicular and/or microvesicular steatosis in Ppara-null and hPPARa mice. However, we were unable to explain why macrovesicular steatosis was found only in Ppara-null mice. Further study is warranted to determine whether or not a PPARc or increase in cholesterol is involved in this regard in the liver of Pparanull mice. A question may arise as to why DGAT1 was induced in the liver of Ppara-null and hPPARa mice, but not in mPPARa mice, though increased in the 1.0 mg/kg dose group. DGAT1 is expressed in organs that produce large amounts of TG, such as liver, small intestine, and adipose tissue (Cases et al. 1998) , which may be regulated by PPARc (Ranganathan et al. 2006; Festuccia et al. 2009 ). The mRNA levels of PPARc were greatly increased in Ppara-null and only slightly in hPPARa and mPPARa mice, but not in mPPARa mice at 5.0 mg/kg dose. Thus, the activation of PPARc may be related to the increased DGAT1 in all genotyped mice. PFOA treatment also induces mitochondrial biogenesis at the transcriptional level with a preferential stimulation of mitochondrial DNA transcription, which occurs by way of the activation of a PPARc coactivator-1a pathway (Walters et al. 2009 ). Indeed, PFOA is also reported to act as an agonist for PPARc (Vanden Heuvel et al. 2006) . However, the question still remains why PPARc could not be activated by APFO treatment in mPPARa mice. Since the activation of PPARa by APFO was weak in hPPARa mice and showed no activation at all in Ppara-null, this may result in increasing the return PPARc.
Our third concern in this study is why APFO treatments increased pro-inflammatory cytokine TNFa in all genotyped mice. TNFa is thought to be an index of Kupffer cell activation (Yoshida et al. 2001) , which may be related to the increase in necrotic (Morgan et al. 2008) or inflammatory cells (Dasarathy 2008) . APFO treatment increased necrotic cells in the livers of mPPARa and hPPARa mice, and inflammatory cell infiltrations in the livers of Pparanull mice, both of which may be related to the increase in TNFa levels; these phenomena are also related to the rise in ALT activity.
Finally, in addition to macro/microvesicular steatosis, hydropic degeneration was characteristically observed in hPPARa and Ppara-null mice. Minata et al. (2010) recently reported that PFOA in the liver was easily excreted into the bile duct in mPPARa mice, but that the excretion in Pparanull mice was less than half that in mPPARa mice. Therefore, PFOA is thought to be much more accumulated in Ppara-null, and perhaps less so in hPPARa mice, compared with that in mPPARa mice. PFOA accumulated in hepatocytes poses a potential risk for mitochondrial dysfunction: APFO treatment results in an increase in the production of oxidative stress (Panaretakis et al. 2001) and in an enhancement of mitochondrial inner membrane permeability, which may disturb the mitochondrial intermembranous electrochemical gradient, thus reducing the ATP production rate (Starkov and Wallace 2002) . A powerful induction of the UCP2 expression following APFO treatment found only in mPPARa mice may serve as protection against mitochondrial damage, because UCP2 is known to be a target gene of PPARa and can inhibit oxidative stress production in mitochondria (Nègre-Salvayre et al. 1997; Kizaki et al. 2002) . Very low levels of UCP2 induction in hPPARa mice and non-induction in Pparanull mice may not be enough to protect mitochondria from PFOA-induced oxidative stress. Furthermore, cellular stress induced by an excessive PFOA accumulation may also damage the endoplasmic reticulum, cytoskeleton, and microtubules, thus impairing excretion of proteins, lipids, and bile acids from hepatocytes. We consider that these abnormalities may eventually lead to the appearance of hydropic degeneration of hepatocytes, preferentially in Ppara-null and hPPARa mice.
In this study, steatosis was not observed in the control Ppara-null mice. This is consistent with the previous report that 24-week-old control Sv/129 Ppara-null mice demonstrated neither apparent steatosis nor increases in hepatic TG contents compared with control wild-type mice . Okiyama et al. (2009) showed the presence of macrovesicular steatosis in the control group of Ppara-null mice, but they have used fat-rich liquid diet as a control. Furthermore, Rosen et al. (2010) reported the presence of significant macrovesicular steatosis in the control Ppara-null mice; such a discrepancy may be derived from the marked difference in mouse age (6-to 9-month-old mice in Rosen's study vs. 14-week-old mice in this study). It is plausible that steatosis may become obvious with age especially in Ppara-null mice, since mitochondrial b-oxidation ability is constitutively lower in Ppara-null mice than in wild-type mice (Aoyama et al. 1998 ).
In conclusion, PPARa function may be very important in protecting against hepatic damage caused by PFOA, a result similar to the findings reported by many laboratories (Minata et al. 2010; Wolf et al. 2008b) . In this regard, the human PPARa function may be weak compared with that of mice. In addition, the expression of the receptor in human liver was 1/10 lower than that in mice or rats (Palmer et al. 1998) . Therefore, hepatic damage may be induced if humans are exposed to high doses of PFOA. In such cases, histopathological findings may resemble those of Ppara-null mice more than mPPARa mice.
